Edition:
United States

Alcobra Ltd (ADHD.OQ)

ADHD.OQ on NASDAQ Stock Exchange Global Market

1.10USD
4:00pm EDT
Change (% chg)

$-0.01 (-0.90%)
Prev Close
$1.11
Open
$1.12
Day's High
$1.12
Day's Low
$1.09
Volume
30,766
Avg. Vol
134,246
52-wk High
$5.75
52-wk Low
$0.83

ADHD.OQ

Chart for ADHD.OQ

About

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $30.59
Shares Outstanding(Mil.): 27.56
Dividend: --
Yield (%): --

Financials

  ADHD.OQ Industry Sector
P/E (TTM): -- 48.48 30.07
EPS (TTM): -0.88 -- --
ROI: -53.74 -2.48 13.05
ROE: -53.74 5.24 14.20

BRIEF-Amir Efrati reports passive stake of 9 pct in Alcobra Ltd

* Amir Efrati reports passive stake of 9 percent in alcobra ltd as on Feb. 22, 2017

Feb 24 2017

BRIEF-Alcobra reports Q4 loss per share $0.22

* Alcobra announces fourth-quarter and full-year 2016 financial results and provides corporate update

Feb 15 2017

BRIEF-Amir Efrati reports 7.5 pct stake in Alcobra Ltd as of Jan. 23

* Amir Efrati reports 7.5 percent stake in Alcobra Ltd as of January 23 - sec filing

Feb 02 2017

Alcobra to stop testing sole drug for ADHD after study fails

Alcobra Ltd said it would abandon evaluating its only experimental drug to treat attention deficit hyperactivity disorder (ADHD), after a failed late-stage study, wiping away more than half the company's value before the bell on Tuesday.

Jan 17 2017

UPDATE 2-Alcobra to stop testing sole drug for ADHD after study fails

Jan 17 Alcobra Ltd said it would abandon evaluating its only experimental drug to treat attention deficit hyperactivity disorder (ADHD), after a failed late-stage study, wiping away more than half the company's value before the bell on Tuesday.

Jan 17 2017

BRIEF-Alcobra reports Phase 3 clinical trial of MDX in adults

* Alcobra reports Phase 3 clinical trial of MDX in adults with ADHD missed primary endpoint

Jan 17 2017

Alcobra's ADHD drug fails late-stage study

Jan 17 Israeli drug developer Alcobra Ltd on Tuesday said its experimental drug to treat attention deficit hyperactivity disorder (ADHD) failed a late-stage study in adult patients.

Jan 17 2017

BRIEF-Alcobra provides update on recent FDA meeting and path forward for MDX clinical development program

* Alcobra provides update on recent FDA meeting and path forward for MDX clinical development program

Jan 09 2017

BRIEF-Alcobra Qtrly loss per share $0.28

* Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S

Nov 15 2016

Alcobra plunges after FDA places hold on ADHD drug

Alcobra Ltd's market value more than halved on Thursday, a day after the company said the U.S. Food and Drug Administration had placed a hold on its lead experimental drug.

Sep 29 2016

More From Around the Web

Earnings vs. Estimates